Literature DB >> 31502562

Biopolymers augment viral vectors based gene delivery.

Balaji Balakrishnan1, Ernest David.   

Abstract

The success of viral vectors mediated gene therapy is still hampered by immunogenicity and insufficient transgene expression. Alternatively, non-viral vectors mediated gene delivery has the advantage of low immunogenicity despite showing low transgene expression. By carefully considering the advantages of each approach, hybrid vectors are currently being developed by modifying the viral vectors using non-viral biopolymers. This review provides an overview of the hybrid vectors currently being developed.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31502562

Source DB:  PubMed          Journal:  J Biosci        ISSN： 0250-5991            Impact factor:   1.826


  52 in total

1.  Delivery of herpes simplex virus vectors through liposome formulation.

Authors:  X Fu; X Zhang
Journal:  Mol Ther       Date:  2001-11       Impact factor: 11.454

Review 2.  Liposome clearance.

Authors:  Tatsuhiro Ishida; Hideyoshi Harashima; Hiroshi Kiwada
Journal:  Biosci Rep       Date:  2002-04       Impact factor: 3.840

3.  Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery.

Authors:  Mark Pandori; David Hobson; Takeshi Sano
Journal:  Virology       Date:  2002-08-01       Impact factor: 3.616

4.  "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.

Authors:  M A Croyle; N Chirmule; Y Zhang; J M Wilson
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

Authors:  C R O'Riordan; A Lachapelle; C Delgado; V Parkes; S C Wadsworth; A E Smith; G E Francis
Journal:  Hum Gene Ther       Date:  1999-05-20       Impact factor: 5.695

6.  Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses.

Authors:  Patricia Yotnda; Dong-Hua Chen; Wah Chiu; Pedro A Piedra; Alan Davis; Nancy Smyth Templeton; Malcolm K Brenner
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

7.  Blood clearance rates of adenovirus type 5 in mice.

Authors:  Ramon Alemany; Kaori Suzuki; David T Curiel
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

8.  Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.

Authors:  Cathryn Mah; Thomas J Fraites; Irene Zolotukhin; Sihong Song; Terence R Flotte; Jon Dobson; Christopher Batich; Barry J Byrne
Journal:  Mol Ther       Date:  2002-07       Impact factor: 11.454

Review 9.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728
View more
  1 in total

1.  The impact of impaired DNA mobility on gene electrotransfer efficiency: analysis in 3D model.

Authors:  Saša Haberl Meglič; Mojca Pavlin
Journal:  Biomed Eng Online       Date:  2021-08-21       Impact factor: 2.819
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.